Marco Donia, Research Group Leader of the TIL group at CCIT (Center for Cancer Immune Therapy) and Professor at the University of Copenhagen, shared a post on LinkedIn:
“What is the rationale behind Neo-Adjuvant Immunotherapy?
A different concept compared to other neo-adjuvant treatments of Cancer. Here, the immunotherapy is given to raise a strong immune response before the cancer is removed by surgery, not to shrink the tumor before the surgery, as for classical cancer treatments.
An excellent new review (by Francesca Fallarino and Christian Blank, 22 September 2025)
Title: Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape
Authors: Francesca Fallarino, Christian U. Blank
Read the Full Article in Nature Reviews Immunology.
Title: Learning from clinical trials of neoadjuvant checkpoint blockade
Authors: Judith M. Versluis, Georgina V. Long, Christian U. Blank
Read the Full Article in Nature Medicine.
More posts featuring Marco Donia on OncoDaily.